Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

D.R. Camidge, H.R. Kim, M.-J. Ahn, J.C.-H. Yang, J.-Y. Han, J.-S. Lee, M.J. Hochmair, J.Y.-C. Li, G.-C. Chang, K.H. Lee, C. Gridelli, A. Delmonte, R. Garcia Campelo, D.-W. Kim, A. Bearz, F. Griesinger, A. Morabito, E. Felip, R. Califano, S. GhoshA. Spira, S.N. Gettinger, M. Tiseo, N. Gupta, J. Haney, D. Kerstein, S. Popat

Research output: Contribution to journalArticle

Original languageItalian
Pages (from-to)2027-2039
Number of pages13
JournalNew England Journal of Medicine
Volume379
Issue number21
DOIs
Publication statusPublished - 2018

Cite this

Camidge, D. R., Kim, H. R., Ahn, M-J., Yang, JC-H., Han, J-Y., Lee, J-S., Hochmair, M. J., Li, JY-C., Chang, G-C., Lee, K. H., Gridelli, C., Delmonte, A., Garcia Campelo, R., Kim, D-W., Bearz, A., Griesinger, F., Morabito, A., Felip, E., Califano, R., ... Popat, S. (2018). Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. New England Journal of Medicine, 379(21), 2027-2039. https://doi.org/10.1056/NEJMoa1810171